DPYD 基因多态性 c.496A>G、c.2194G>A 与 c.85T>C 及氟尿嘧啶类方案严重不良反应风险
本研究纳入 503 例接受氟尿嘧啶类方案治疗的成人癌症患者,评估 DPYD c.496A>G、c.2194G>A 和 c.85T>C 三个多态性与 ≥3 级不良反应的关系。结果显示 c.496A>G 变异携带者发生 ≥3 级不良反应的比值显著增高,c.2194G>A 有增高趋势,c.85T>C 未见关联。
要点
- c.496A>G 变异携带者 ≥3 级不良反应风险显著增高,OR=5.20(95%CI 1.88-14.3)。
- c.2194G>A 变异携带者风险有增高趋势,OR=1.88(95%CI 0.95-3.73)。
- c.85T>C 与 ≥3 级不良反应未见明显关联。
核心结论
- DPYD c.496A>G 和可能的 c.2194G>A 变异需要考虑纳入 DPYD 基因分型 panel。
研究设计与样本
- 连续纳入接受氟尿嘧啶类方案治疗的成人癌症患者,检测标准及待测 DPYD 变异,若含伊立替康则检测 UGT1A1*28,并监测 ≥3 级与 0-2 级不良反应。
- 共纳入 503 例患者,82.3% 为结直肠癌;对每个待测多态性,变异携带者与野生型对照进行最优全匹配联合精确匹配(匹配年龄、性别、癌症类型、氟尿嘧啶类型、DPYD 活性评分、伊立替康/UGT1A1 使用、辅助治疗、放疗、生物治疗及另外两个待测多态性基因型)。
主要发现
- 283 例(56.3%)发生 ≥3 级不良反应,主要为腹泻和中性粒细胞减少。
- c.496A>G 变异携带者(n=127)较对照(n=376)≥3 级不良反应的比值更高:OR=5.20(95%CI 1.88-14.3),贝叶斯 OR=5.24(95%CrI 3.06-9.12)。
- c.2194G>A 变异携带者(n=58)较对照(n=432)≥3 级不良反应的比值有增高趋势:OR=1.88(95%CI 0.95-3.73),贝叶斯 OR=1.90(95%CrI 1.03-3.56)。
- c.85T>C 变异携带者(n=206)与对照(n=284)相比,未显示与 ≥3 级不良反应相关。
临床怎么用
- 对于接受氟尿嘧啶类方案治疗的患者,可考虑检测 DPYD c.496A>G 以识别严重不良反应高风险者。
- c.2194G>A 的临床价值尚需进一步确认,暂不宜单独作为剂量调整依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Cancer patients with reduced dihydropyrimidine dehydrogenase (DPD) activity are at increased risk of severe fluoropyrimidine (FP)-related adverse events (AE). Guidelines recommend FP dosing adjusted to genotype-predicted DPD activity based on four DPYD variants (rs3918290, rs55886062, rs67376798 and rs56038477). We evaluated the relationship between three further DPYD polymorphisms: c.496A>G (rs2297595), *6 c.2194G>A (rs1801160) and *9A c.85T>C (rs1801265) and the risk of severe AEs. METHODS: Consecutive FP-treated adult patients were genotyped for "standard" and tested DPYD variants, and for UGT1A1*28 if irinotecan was included, and were monitored for the occurrence of grade ≥3 (National Cancer Institute Common Terminology Criteria) vs. grade 0-2 AEs. For each of the tested polymorphisms, variant allele carriers were matched to respective wild type controls (optimal full matching combined with exact matching, in respect to: age, sex, type of cancer, type of FP, DPYD activity score, use of irinotecan/UGT1A1, adjuvant therapy, radiotherapy, biological therapy and genotype on the remaining two tested polymorphisms). RESULTS: Of the 503 included patients (82.3% colorectal cancer), 283 (56.3%) developed grade ≥3 AEs, mostly diarrhoea and neutropenia. Odds of grade ≥3 AEs were higher in c.496A>G variant carriers (n = 127) than in controls (n = 376) [OR = 5.20 (95% CI 1.88-14.3), Bayesian OR = 5.24 (95% CrI 3.06-9.12)]. Odds tended to be higher in c.2194G>A variant carriers (n = 58) than in controls (n = 432) [OR = 1.88 (0.95-3.73), Bayesian OR = 1.90 (1.03-3.56)]. c.85T>C did not appear associated with grade ≥3 AEs (206 variant carriers vs. 284 controls). CONCLUSION: DPYD c.496A>G and possibly c.2194G>A variants might need to be considered for inclusion in the DPYD genotyping panel.
引用
- Božina N, Bilić I, Ganoci L, et al. DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. Br J Clin Pharmacol. 2021. PMID: 34780066. doi:10.1111/bcp.15144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。